Sequent Medical announced that it has received CE Mark approval for its Single-Layer family of Web aneurysm embolisation devices and has commenced a controlled release of these new models in select neurovascular centres in Europe, according to the company.
The Single-Layer family offers a lower profile and excellent navigability that will enable physicians to treat a broader range of aneurysms with the Web platform, the company said.
Sequent Medical advised that the Web is a low-porosity, intrasaccular neurovascular embolisation device and is designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and promote rapid periprocedural stasis. The Web enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.
According to Sequent Medical, the single-layer configurations are created with the company’s MicroBraid technology, a dense mesh constructed from a large number of extremely fine nitinol wires. MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity, and profile across device sizes. The Single-Layer family consists of two separate product configurations, the Web SL and Web SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies. Both configurations are available in multiple sizes ranging from 4mm to 11mm and are designed for delivery through Sequent Medical’s Via microcatheters.
“Sequent Medical has responded to physicians’ requests in developing the Web SL configurations,” commented Laurent Pierot, head of the Department of Radiology at Maison Blanche Hospital in Reims, France. “The SL family promises to expand the range of aneurysms physicians can treat with the Web, while continuing to offer the familiar, straightforward procedure we have come to value with the Web DL.”